• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载肝素-去氧胆酸(DOCA)纳米粒子的 QD 对胃肠道的成像。

Imaging of the GI tract by QDs loaded heparin-deoxycholic acid (DOCA) nanoparticles.

机构信息

Department of Chemical and Biological Engineering, Korea National University of Transportation, Chungbuk 380-702, Republic of Korea.

出版信息

Carbohydr Polym. 2012 Nov 6;90(4):1461-8. doi: 10.1016/j.carbpol.2012.07.016. Epub 2012 Jul 16.

DOI:10.1016/j.carbpol.2012.07.016
PMID:22944403
Abstract

This study presents an approach to deliver non invasive, near-IR imaging agent using oral delivery system. Low molecular weight heparin (LMWH)-deoxycholic acid (DOCA)/(LHD) nanoparticles formed by a self-assembly method was prepared to evaluate their physicochemical properties and oral absorption in vitro and in vivo. Near-IR QDs were prepared and loaded into LHD nanoparticles for imaging of the gastro-intestinal (GI) tract absorption. Q-LHD nanoparticles were almost spherical in shape with diameters of 194-217 nm. The size and fluorescent intensity of the Q-LHD nanoparticles were stable in 10% FBS solution and retained their fluorescent even after 5 days of incubation. Cell viability of Q-LHD nanoparticles maintained in the range of 80-95% for 24h incubation. No damage was found in tissues or organs during animal experiments. The in vivo oral absorption of Q-LHD was observed in SKH1 mice for 3h under different doses. From the results, we confirmed that Q-LHD was absorbed mostly into the ileum of small intestine containing intestinal bile acid transporter as observed in TEM and molecular imaging system. Our designed nanoparticles could be administered orally for bio-imaging and studying the bio-distribution of drug.

摘要

本研究提出了一种通过口服给药系统递送非侵入性近红外成像剂的方法。通过自组装方法制备了低分子量肝素(LMWH)-脱氧胆酸(DOCA)/(LHD)纳米粒子,以评估其理化性质以及在体外和体内的口服吸收。制备了近红外 QD 并将其装载到 LHD 纳米粒子中,以对胃肠道(GI)吸收进行成像。Q-LHD 纳米粒子呈近球形,直径为 194-217nm。在 10%FBS 溶液中,Q-LHD 纳米粒子的尺寸和荧光强度稳定,即使孵育 5 天后仍保持荧光。Q-LHD 纳米粒子的细胞活力在 24h 孵育期间保持在 80-95%的范围内。在动物实验过程中,未发现组织或器官受损。在不同剂量下,在 SKH1 小鼠中观察到 Q-LHD 在 3h 内的体内口服吸收。结果表明,Q-LHD 主要被吸收到含有肠胆酸转运体的小肠回肠中,这在 TEM 和分子成像系统中得到了观察。我们设计的纳米粒子可以口服给药用于生物成像和研究药物的生物分布。

相似文献

1
Imaging of the GI tract by QDs loaded heparin-deoxycholic acid (DOCA) nanoparticles.载肝素-去氧胆酸(DOCA)纳米粒子的 QD 对胃肠道的成像。
Carbohydr Polym. 2012 Nov 6;90(4):1461-8. doi: 10.1016/j.carbpol.2012.07.016. Epub 2012 Jul 16.
2
Oral delivery of near-infrared quantum dot loaded micelles for noninvasive biomedical imaging.口服近红外量子点负载胶束用于无创生物医学成像。
ACS Appl Mater Interfaces. 2012 Aug;4(8):3880-7. doi: 10.1021/am301048m. Epub 2012 Aug 10.
3
Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.低分子量肝素和脱氧胆酸缀合物口服片剂的药代动力学评价:一种新型口服抗凝剂。
Thromb Haemost. 2011 Jun;105(6):1060-71. doi: 10.1160/TH10-07-0484. Epub 2011 Mar 24.
4
Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.脱氧胆酸-肝素缀合物作为新型口服抗凝剂的吸收研究
J Control Release. 2007 Jul 16;120(1-2):4-10. doi: 10.1016/j.jconrel.2007.03.008. Epub 2007 Mar 20.
5
Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.肝素与脱氧胆酸化学偶联物在水性制剂中的口服给药。
Thromb Res. 2006;117(4):419-27. doi: 10.1016/j.thromres.2005.03.027.
6
Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.低分子量肝素与脱氧胆酸口服活性化学偶联物在大鼠、小鼠和猴子体内的疗效
J Control Release. 2006 Apr 10;111(3):290-8. doi: 10.1016/j.jconrel.2005.12.011. Epub 2006 Feb 23.
7
High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.口服活性低分子肝素衍生物具有高效的抗血管生成和低抗凝作用。
J Control Release. 2010 Dec 20;148(3):317-26. doi: 10.1016/j.jconrel.2010.09.014. Epub 2010 Sep 30.
8
A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.一种新开发的用于治疗深静脉血栓的口服肝素衍生物:非人灵长类动物研究。
J Control Release. 2007 Nov 6;123(2):155-63. doi: 10.1016/j.jconrel.2007.08.007. Epub 2007 Aug 16.
9
Physicochemical conjugation with deoxycholic acid and dimethylsulfoxide for heparin oral delivery.物理化学偶联法用去氧胆酸和二甲基亚砜进行肝素口服递送。
Bioconjug Chem. 2011 Jul 20;22(7):1451-8. doi: 10.1021/bc100594v. Epub 2011 Jun 8.
10
Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.新型肝素衍生物固体制剂的抗凝疗效。
Mol Pharm. 2010 Jun 7;7(3):836-43. doi: 10.1021/mp900319k.

引用本文的文献

1
Engineering of small-molecule lipidic prodrugs as novel nanomedicines for enhanced drug delivery.小分子脂质前药的工程设计作为新型纳米药物以增强药物传递。
J Nanobiotechnology. 2022 Jan 24;20(1):49. doi: 10.1186/s12951-022-01257-4.
2
Production and Status of Bacterial Cellulose in Biomedical Engineering.细菌纤维素在生物医学工程中的生产与现状
Nanomaterials (Basel). 2017 Sep 4;7(9):257. doi: 10.3390/nano7090257.
3
Bile acid transporter-mediated oral drug delivery.胆汁酸转运体介导的口服药物递送。
J Control Release. 2020 Nov 10;327:100-116. doi: 10.1016/j.jconrel.2020.07.034. Epub 2020 Jul 22.
4
Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.硫酸化非糖基化糖胺聚糖类似物作为用于各种病理的新型药物发现平台。
Curr Med Chem. 2020;27(21):3412-3447. doi: 10.2174/0929867325666181120101147.
5
Strategies to Overcome Heparins' Low Oral Bioavailability.克服肝素口服生物利用度低的策略。
Pharmaceuticals (Basel). 2016 Jun 29;9(3):37. doi: 10.3390/ph9030037.
6
Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine.胆汁盐在药学中的多方面应用:聚焦于纳米医学。
Int J Nanomedicine. 2015 Jun 12;10:3955-71. doi: 10.2147/IJN.S82558. eCollection 2015.
7
Recent advances in application of biosensors in tissue engineering.生物传感器在组织工程中的应用新进展。
Biomed Res Int. 2014;2014:307519. doi: 10.1155/2014/307519. Epub 2014 Aug 6.
8
Heparin based nanoparticles for cancer targeting and noninvasive imaging.基于肝素的纳米颗粒用于癌症靶向和非侵入性成像。
Quant Imaging Med Surg. 2012 Sep;2(3):219-26. doi: 10.3978/j.issn.2223-4292.2012.09.01.